Adaani E. Frost, MD

Professor of Medicine, Institute for Academic Medicine
Houston Methodist
Weill Cornell Medical College


Publications

Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial
Coghlan, JG, Galiè, N, Barberà, JA, Frost, AE, Ghofrani, H-A, Hoeper, MM, Kuwana, M, McLaughlin, VV, Peacock, AJ, Simonneau, G, Vachiéry, J-L, Blair, C, Gillies, H, Miller, KL, Harris, JHN, Langley, J, Rubin, LJ & AMBITION investigators 2016, Annals of the Rheumatic Diseases. DOI:

Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study
Hoeper, MM, McLaughlin, VV, Barberá, JA, Frost, AE, Ghofrani, HA, Peacock, AJ, Simonneau, G, Rosenkranz, S, Oudiz, RJ, White, RJ, Miller, KL, Langley, J, Harris, JHN, Blair, C, Rubin, LJ & Vachiery, JL 2016, The Lancet Respiratory Medicine, vol 4, no. 11, pp. 894-901. DOI:

Endothelin-1 pathway polymorphisms and outcomes in pulmonary arterial hypertension
Benza, RL, Gomberg-Maitland, M, Demarco, T, Frost, AE, Torbicki, A, Langleben, D, Pulido, T, Correa-Jaque, P, Passineau, MJ, Wiener, HW, Tamari, M, Hirota, T, Kubo, M & Tiwari, HK 2015, American Journal of Respiratory and Critical Care Medicine, vol 192, no. 11, pp. 1345-1354. DOI:

Long-term safety and efficacy of imatinib in pulmonary arterial hypertension
Frost, AE, Barst, RJ, Hoeper, MM, Chang, HJ, Frantz, RP, Fukumoto, Y, Galié, N, Hassoun, PM, Klose, H, Matsubara, H, Morrell, NW, Peacock, AJ, Pfeifer, M, Simonneau, G, Tapson, VF, Torres, F, Dario Vizza, C, Lawrence, D, Yang, W, Felser, JM, Quinn, DA & Ghofrani, HA 2015, Journal of Heart and Lung Transplantation, vol 34, no. 11, pp. 1366-1375. DOI:

Five-year outcomes of patients enrolled in the REVEAL registry
Farber, HW, Miller, DP, Poms, AD, Badesch, DB, Frost, AE, Muros-Le Rouzic, E, Romero, AJ, Benton, WW, Elliott, CG, McGoon, MD & Benza, RL 2015, Chest, vol 148, no. 4, pp. 1043-1054. DOI:

Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension
Galie, N, Barbera, JA, Frost, AE, Ghofrani, HA, Hoeper, MM, McLaughlin, VV, Peacock, AJ, Simonneau, G, Vachiery, JL, Grunig, E, Oudiz, RJ, Vonk-Noordegraaf, A, White, RJ, Blair, C, Gillies, H, Miller, KL, Harris, JHN, Langley, J & Rubin, LJ 2015, New England Journal of Medicine, vol 373, no. 9, pp. 834-844. DOI:

Validation of two predictive models for survival in pulmonary arterial hypertension
Sitbon, O, Benza, RL, Badesch, DB, Barst, RJ, Elliott, CG, Gressin, V, Lemarié, JC, Miller, DP, Rouzic, EML, Simonneau, G, Frost, AE, Farber, HW, Humbert, M & McGoon, MD 2015, European Respiratory Journal, vol 46, no. 1, pp. 152-164. DOI:

Correction to Circulating Collagen Biomarkers as Indicators of Disease Severity in Pulmonary Arterial Hypertension [J Am Coll Cardiol HF, (2014), 2, 412-421]
Safdar, Z, Tamez, E, Chan, W, Arya, B, Ge, Y, Deswal, A, Bozkurt, B, Frost, A & Entman, M 2015, JACC: Heart Failure, vol 3, no. 4, pp. 345. DOI:

Prognostic implications of serial risk score assessments in patients with pulmonary arterial hypertension: A Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) analysis
Benza, RL, Miller, DP, Foreman, AJ, Frost, AE, Badesch, DB, Benton, WW & McGoon, MD 2015, Journal of Heart and Lung Transplantation, vol 34, no. 3, pp. 356-361. DOI:

Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance
Farber, HW, Miller, DP, McGoon, MD, Frost, AE, Benton, WW & Benza, RL 2015, Journal of Heart and Lung Transplantation, vol 34, no. 3, pp. 362-368. DOI:

Hospitalization and survival in patients using epoprostenol for injection in the PROSPECT observational study
Frantz, RP, Schilz, RJ, Chakinala, MM, Badesch, DB, Frost, AE, McLaughlin, VV, Barst, RJ, Rosenberg, DM, Miller, DP, Hartline, BK, Benton, WW & Farber, HW 2015, Chest, vol 147, no. 2, pp. 484-494. DOI:

Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study
Chin, KM, Badesch, DB, Robbins, IM, Tapson, VF, Palevsky, HI, Kim, NH, Kawut, SM, Frost, A, Benton, WW, Lemarie, JC, Bodin, F, Rubin, LJ & McLaughlin, V 2014, American Heart Journal, vol 167, no. 2. DOI:

Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension
Simonneau, G, Rubin, LJ, Galiè, N, Barst, RJ, Fleming, TR, Frost, A, Engel, P, Kramer, MR, Serdarevic-Pehar, M, Layton, GR, Sitbon, O & Badesch, DB 2014, Journal of Heart and Lung Transplantation, vol 33, no. 7, pp. 689-697. DOI:

Circulating Collagen Biomarkers as Indicators of Disease Severity in Pulmonary Arterial Hypertension
Safdar, Z, Tamez, E, Chan, W, Arya, B, Ge, Y, Deswal, A, Bozkurt, B, Frost, A & Entman, M 2014, JACC: Heart Failure, vol 2, no. 4, pp. 412-421. DOI:

Updated treatment algorithm of pulmonary arterial hypertension
Galiè, N, Corris, PA, Frost, A, Girgis, RE, Granton, J, Jing, ZC, Klepetko, W, McGoon, MD, McLaughlin, VV, Preston, IR, Rubin, LJ, Sandoval, J, Seeger, W & Keogh, A 2013, Journal of the American College of Cardiology, vol 62, no. 25 SUPPL.. DOI:

Survival in pulmonary arterial hypertension patients awaiting lung transplantation
Gomberg-Maitland, M, Glassner-Kolmin, C, Watson, S, Frantz, R, Park, M, Frost, A, Benza, RL & Torres, F 2013, Journal of Heart and Lung Transplantation, vol 32, no. 12, pp. 1179-1186. DOI:

Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: A REVEAL registry analysis
Frost, AE, Badesch, DB, Miller, DP, Benza, RL, Meltzer, LA & McGoon, MD 2013, Chest, vol 144, no. 5, pp. 1521-1529. DOI:

Systemic BP and heart rate as prognostic indicators in pulmonary arterial hypertension
Bersohn, MM, Turner, MP, Traiger, GL, Frost, AE & Shapiro, S 2013, Chest, vol 144, no. 3, pp. 959-965. DOI:

Referral of patients with pulmonary hypertension diagnoses to tertiary pulmonary hypertension centers: The multicenter RePHerral study
Deaño, RC, Glassner-Kolmin, C, Rubenfire, M, Frost, A, Visovatti, S, McLaughlin, VV & Gomberg-Maitland, M 2013, JAMA Internal Medicine, vol 173, no. 10, pp. 887-893. DOI:

Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: Results of the randomized IMPRES study
Hoeper, MM, Barst, RJ, Bourge, RC, Feldman, J, Frost, AE, Galié, N, Gómez-Sánchez, MA, Grimminger, F, Grünig, E, Hassoun, PM, Morrell, NW, Peacock, AJ, Satoh, T, Simonneau, G, Tapson, VF, Torres, F, Lawrence, D, Quinn, DA & Ghofrani, HA 2013, Circulation, vol 127, no. 10, pp. 1128-1138. DOI: